Wenlafaksyna, sertralina i escitalopram – 3 leki, które bardzo dobrze znamy, w nieco innej odsłonie Opis przypadku
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2017
Słowa kluczowe:
wenlafaksyna, sertralina, escitalopram, lęk, lęk paniczny, zaburzenia obsesyjno-kompulsyjne
##plugins.themes.bootstrap3.article.main##
Abstrakt
Podczas wyboru terapii psychiatrycznej należy brać pod uwagę nie tylko samą substancję, ale także jej dawkę i historię leczenia pacjenta. W pracy zaprezentowano 3 przypadki, w których uwzględnienie tych czynników znacząco wpłynęło na skuteczność terapii.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Polikowska , M. (2017). Wenlafaksyna, sertralina i escitalopram – 3 leki, które bardzo dobrze znamy, w nieco innej odsłonie . Medycyna Faktów , 10(2(35), 152-157. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2157
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Wciórka J., Pużyński S., Rybakowski J.: Psychiatria. T. 2. Elsevier Urban & Partner, Wrocław 2012.
2. Thase M.E., Shelton R.C., Khan A.: Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies. J. Clin. Psychopharmacol. 2006; 26: 250-258.
3. Kennedy S.H., Gorwood P.: Successful management of major depressive disorder. Future Medicine Ltd, London 2014: 37.
4. Bazire S.: Przewodnik leków psychotropowych. Via Medica, Gdańsk 2014: 249.
5. Debonnel G., Saint-André E., Hébert C. et al.: Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Int. J. Neuropsychopharmacol. 2007; 10: 51-61.
6. Bauer M., Tharmanathan P., Volz H.P. et al.: The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur. Arch. Psychiatry Clin. Neurosci. 2009; 259: 172-185.
7. Anderson I.M.: Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J. Affect. Disord. 2000; 58: 19-36.
8. Thase M.: Treatment of anxiety disorders with venlafaxine XR. Expert Rev. Neurother. 2006; 6(3): 269-282.
9. Montoya A., Bruins R., Katzman M., Blier P.: The noradrenergic paradox: implications in the management of depression and anxiety. Neuropsychiatr. Dis. Treat. 2016; 12: 541-557.
10. Zullino D., Chatton A., Fresard E. et al.: Venlafaxine versus applied relaxation for generalized anxiety disorder: a randomized controlled study on clinical and electrophysiological outcomes. Psychiatr. Q. 2015; 86(1): 69-82.
11. Thase M.E., Entsuah A.R., Rudolph R.L.: Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry 2001; 178: 234-241.
12. Soomro G.M.: Obsessive compulsive disorder. BMJ Clin. Evid. 2012; 2012.
13. Cipriani A., Furukawa T.A., Salanti G. et al.: Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009; 373: 746-758.
14. Łoza B.: 30 lat SSRI: starsze i nowsze leki z grupy SSRI. Neuropsychiatria. Przegląd Kliniczny 2012; 4(4): 214-219.
15. Skapinakis P., Caldwell D., Hollingworth W. et al.: A systematic review of the clinical effectiveness and cost-effectiveness of pharmacological and psychological interventions for the management of obsessive-compulsive disorder in children/adolescents and adults. Health Technol. Assess. 2016; 20(43): 1-392.
16. Skarphedinsson G., Weidle B., Ivarsson T.: Sertraline Treatment of Nonresponders to Extended Cognitive-Behavior Therapy in Pediatric Obsessive- Compulsive Disorder. J. Child Adolesc. Psychopharmacol. 2015; 25(7): 574-579.
17. Choi Y.J.: Efficacy of treatments for patients with obsessive-compulsive disorder: a systematic review. J. Am. Acad. Nurse Pract. 2009; 21(4): 207-213.
18. WHO: Depression. Fact sheets. Aktualizacja: luty 2017.
19. Goodwin R.D., Gorman J.M.: Psychopharmacologic treatment of generalized anxiety disorder and the risk of major depression. Am. J. Psychiatry 2002; 159: 1935-1937.
20. Wittchen H.U., Essau C.A.: Comorbidity and mixed anxiety-depressive disorders: is there epidemiologic evidence? J. Clin. Psychiatry 1993; 54(supl.): 9-15.
21. Rzewuska M.: Leczenie zaburzeń nerwicowych. W: Rzewuska M. (red.): Leczenie zaburzeń psychicznych. PZWL, Warszawa 2003: 100-139.
22. Stahl S.M., Gergel I., Li D.: Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 2003; 64: 1322-1327.
23. Davidson J., Bose A., Su G.: Escitalopram in the treatment of generalized anxiety disorder. [poster] 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologium; 2002 Jun 23–27, Montreal, Canada.
24. Łoza B.: Escitalopram: odkrycie leku i jego rozwój. Neuropsychiatria. Przegląd Kliniczny 2011; 3(1): 5-14.
2. Thase M.E., Shelton R.C., Khan A.: Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies. J. Clin. Psychopharmacol. 2006; 26: 250-258.
3. Kennedy S.H., Gorwood P.: Successful management of major depressive disorder. Future Medicine Ltd, London 2014: 37.
4. Bazire S.: Przewodnik leków psychotropowych. Via Medica, Gdańsk 2014: 249.
5. Debonnel G., Saint-André E., Hébert C. et al.: Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Int. J. Neuropsychopharmacol. 2007; 10: 51-61.
6. Bauer M., Tharmanathan P., Volz H.P. et al.: The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur. Arch. Psychiatry Clin. Neurosci. 2009; 259: 172-185.
7. Anderson I.M.: Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J. Affect. Disord. 2000; 58: 19-36.
8. Thase M.: Treatment of anxiety disorders with venlafaxine XR. Expert Rev. Neurother. 2006; 6(3): 269-282.
9. Montoya A., Bruins R., Katzman M., Blier P.: The noradrenergic paradox: implications in the management of depression and anxiety. Neuropsychiatr. Dis. Treat. 2016; 12: 541-557.
10. Zullino D., Chatton A., Fresard E. et al.: Venlafaxine versus applied relaxation for generalized anxiety disorder: a randomized controlled study on clinical and electrophysiological outcomes. Psychiatr. Q. 2015; 86(1): 69-82.
11. Thase M.E., Entsuah A.R., Rudolph R.L.: Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry 2001; 178: 234-241.
12. Soomro G.M.: Obsessive compulsive disorder. BMJ Clin. Evid. 2012; 2012.
13. Cipriani A., Furukawa T.A., Salanti G. et al.: Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009; 373: 746-758.
14. Łoza B.: 30 lat SSRI: starsze i nowsze leki z grupy SSRI. Neuropsychiatria. Przegląd Kliniczny 2012; 4(4): 214-219.
15. Skapinakis P., Caldwell D., Hollingworth W. et al.: A systematic review of the clinical effectiveness and cost-effectiveness of pharmacological and psychological interventions for the management of obsessive-compulsive disorder in children/adolescents and adults. Health Technol. Assess. 2016; 20(43): 1-392.
16. Skarphedinsson G., Weidle B., Ivarsson T.: Sertraline Treatment of Nonresponders to Extended Cognitive-Behavior Therapy in Pediatric Obsessive- Compulsive Disorder. J. Child Adolesc. Psychopharmacol. 2015; 25(7): 574-579.
17. Choi Y.J.: Efficacy of treatments for patients with obsessive-compulsive disorder: a systematic review. J. Am. Acad. Nurse Pract. 2009; 21(4): 207-213.
18. WHO: Depression. Fact sheets. Aktualizacja: luty 2017.
19. Goodwin R.D., Gorman J.M.: Psychopharmacologic treatment of generalized anxiety disorder and the risk of major depression. Am. J. Psychiatry 2002; 159: 1935-1937.
20. Wittchen H.U., Essau C.A.: Comorbidity and mixed anxiety-depressive disorders: is there epidemiologic evidence? J. Clin. Psychiatry 1993; 54(supl.): 9-15.
21. Rzewuska M.: Leczenie zaburzeń nerwicowych. W: Rzewuska M. (red.): Leczenie zaburzeń psychicznych. PZWL, Warszawa 2003: 100-139.
22. Stahl S.M., Gergel I., Li D.: Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 2003; 64: 1322-1327.
23. Davidson J., Bose A., Su G.: Escitalopram in the treatment of generalized anxiety disorder. [poster] 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologium; 2002 Jun 23–27, Montreal, Canada.
24. Łoza B.: Escitalopram: odkrycie leku i jego rozwój. Neuropsychiatria. Przegląd Kliniczny 2011; 3(1): 5-14.